TC-5214 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
Conditions
Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
Trial Timeline
Jan 1, 2011 → May 1, 2011
NCT ID
NCT01239771About TC-5214 + Placebo
TC-5214 + Placebo is a phase 1 stage product being developed by AstraZeneca for Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.. The current trial status is completed. This product is registered under clinical trial identifier NCT01239771. Target conditions include Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment..
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01392820 | Phase 1 | Completed |
| NCT01239771 | Phase 1 | Completed |
| NCT01197508 | Phase 3 | Completed |
| NCT01180400 | Phase 3 | Completed |
| NCT01175564 | Phase 1 | Completed |
| NCT01152554 | Phase 3 | Completed |
| NCT01157078 | Phase 3 | Completed |
| NCT01153347 | Phase 3 | Completed |
Competing Products
15 competing products in Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM150 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| Esmirtazapine | Merck | Phase 3 | 77 |
| Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy | Roche | Phase 2 | 52 |
| PF-06648671 + Midazolam + Placebo | Pfizer | Phase 1 | 32 |
| PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo | Pfizer | Phase 1 | 32 |
| Vitamin D + Sham Exercise + Vitamin D + Exercise | Pfizer | Phase 1 | 32 |
| HSK3486 + HSK3486 + HSK3486 + HSK3486 | Haisco Pharmaceutical Group | Phase 1 | 30 |
| Padsevonil | UCB | Phase 1 | 30 |
| TD-1439 + Placebo | Theravance Biopharma | Phase 1 | 28 |
| TD-0714 + Placebo | Theravance Biopharma | Phase 1 | 28 |